Phase II Study to Evaluate the Cardiac Safety of 2 Doses of CHF5993 Both Combined With CHF1535 BID Versus CHF1535 BID in Patients With Moderate to Severe COPD

NCT01584505 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

191

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG: CHF1535 + CHF5992 dose 1 BID
DRUG: CHF1535 + CHF5992 dose2 BID
DRUG: CHF1535 daily dose

Sponsor

Chiesi Farmaceutici S.p.A.